Stoke Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Ian Smith
Chief executive officer
US$248.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1yr |
| CEO ownership | n/a |
| Management average tenure | 1.2yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
Jan 12
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Dec 05Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating
Dec 04Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Oct 09Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Aug 25Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
Aug 15Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
May 20Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Apr 16Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Apr 05We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Feb 26Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Feb 16Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30CEO
Ian Smith (59 yo)
Mr. Ian F. Smith, CPA, ACA, is CEO of Stoke Therapeutics, Inc. from October 6, 2025 and serves as its Director since September 19, 2023 and served as its Interim CEO from March 19, 2025 to October 6, 2025....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1yr | US$248.25k | no data | |
| Co-Founder & Independent Director | no data | US$130.95k | 0.48% $ 9.5m | |
| Chief Financial Officer | 1.8yrs | US$4.69m | 0.017% $ 340.9k | |
| Advisor & Director | 1yr | US$5.61m | 0.19% $ 3.7m | |
| Chief Medical Officer | 8.4yrs | US$2.47m | 0.069% $ 1.4m | |
| Co-Founder | no data | no data | no data | |
| Director of Communications & Investor Relations | 1.2yrs | no data | no data | |
| Corporate Secretary & General Counsel | 5.2yrs | no data | 0.049% $ 966.3k | |
| Chief People Officer | 1.2yrs | no data | no data | |
| Chief of Corporate Affairs & Strategic Partnerships | less than a year | no data | no data | |
| Chief Patient Officer | 1.9yrs | no data | 0.017% $ 344.3k | |
| Chief Regulatory Officer | less than a year | no data | no data |
Experienced Management: STOK's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$248.25k | no data | |
| Co-Founder & Independent Director | 11.8yrs | US$130.95k | 0.48% $ 9.5m | |
| Advisor & Director | 8.4yrs | US$5.61m | 0.19% $ 3.7m | |
| Independent Director | 10.7yrs | US$152.31k | 3.17% $ 62.8m | |
| Independent Director | 10.5yrs | US$135.95k | 0.038% $ 744.5k | |
| Independent Director | 5.6yrs | US$136.14k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$137.39k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$140.95k | 0% $ 0 | |
| Chairman of the Board | 7.5yrs | US$150.65k | 0.053% $ 1.1m |
Experienced Board: STOK's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/22 18:21 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stoke Therapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |